A Goldhirsch

Summary

Affiliation: International Breast Cancer Study Group
Country: Switzerland

Publications

  1. ncbi request reprint First--select the target: better choice of adjuvant treatments for breast cancer patients
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Switzerland
    Ann Oncol 17:1772-6. 2006
  2. pmc Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
    E Montagna
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Br J Cancer 98:1745-52. 2008
  3. pmc Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
  4. pmc Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
    A Goldhirsch
    International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 24:2206-23. 2013
  5. ncbi request reprint Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient
    Aron Goldhirsch
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy International Breast Cancer Study Group IBCSG, Bern, Switzerland Medical Oncology, Ospedale Regionale di Lugano, Lugano, Switzerland Electronic address
    Breast 22:S3-7. 2013
  6. pmc International Web-based consultation on priorities for translational breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Breast Cancer Res 9:R81. 2007
  7. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
  8. pmc Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    A Goldhirsch
    International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:1736-47. 2011
  9. ncbi request reprint Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
    Ann Oncol 18:1133-44. 2007
  10. ncbi request reprint Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 16:1569-83. 2005

Detail Information

Publications117 found, 100 shown here

  1. ncbi request reprint First--select the target: better choice of adjuvant treatments for breast cancer patients
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Switzerland
    Ann Oncol 17:1772-6. 2006
    ..This commentary midway between St Gallen meetings, therefore, emphasizes how new information influences algorithms for selecting adjuvant therapy in a rapidly changing environment...
  2. pmc Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer
    E Montagna
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Br J Cancer 98:1745-52. 2008
    ..High degree of Ki-67 staining and presence of PVI were also indicators of higher risk of early relapse. These factors should be considered in therapeutic algorithms for LABC...
  3. pmc Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 20:1319-29. 2009
    ..The threshold for indication of each systemic treatment modality thus depends on different criteria which have been separately listed to clarify the therapeutic decision-making algorithm...
  4. pmc Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
    A Goldhirsch
    International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 24:2206-23. 2013
    ..Detailed decisions on treatment will as always involve clinical consideration of disease extent, host factors, patient preferences and social and economic constraints. ..
  5. ncbi request reprint Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient
    Aron Goldhirsch
    Department of Medicine, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy International Breast Cancer Study Group IBCSG, Bern, Switzerland Medical Oncology, Ospedale Regionale di Lugano, Lugano, Switzerland Electronic address
    Breast 22:S3-7. 2013
    ..Personalized treatments are likely to improve substantially with increasingly accurate determination of their targets and by using risk- and toxicity-modulated therapies. ..
  6. pmc International Web-based consultation on priorities for translational breast cancer research
    Mitch Dowsett
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, UK
    Breast Cancer Res 9:R81. 2007
    ..We therefore conducted an international Web-based consultation of breast cancer professionals to identify the topics most widely considered to be of highest priority...
  7. pmc Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
    Laura Orlando
    Unit of Research in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    BMC Cancer 6:225. 2006
    ..We therefore tested the activity of the combination of Trastuzumab with metronomic, low dose chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer (MBC)...
  8. pmc Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
    A Goldhirsch
    International Breast Cancer Study Group, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 22:1736-47. 2011
    ..Broad treatment recommendations are presented, recognizing that detailed treatment decisions need to consider disease extent, host factors, patient preferences, and social and economic constraints...
  9. ncbi request reprint Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
    Ann Oncol 18:1133-44. 2007
    ..Recommendations are provided not as specific therapy guidelines but rather as a general guidance emphasizing main principles for tailoring therapeutic choice...
  10. ncbi request reprint Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005
    A Goldhirsch
    International Breast Cancer Study Group, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
    Ann Oncol 16:1569-83. 2005
    ....
  11. ncbi request reprint Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor
    M Colleoni
    European Institute of Oncology, Milan, Italy
    Ann Oncol 16:716-25. 2005
    ..Controversy persists about whether chemotherapy benefits all breast cancer patients...
  12. ncbi request reprint Primary chemotherapy in operable breast cancer with favorable prognostic factors: a pilot study evaluating the efficacy of a regimen with a low subjective toxic burden containing vinorelbine, 5-fluorouracil and folinic acid (FLN)
    F Nole
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 10:993-6. 1999
    ....
  13. ncbi request reprint Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer
    M Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 19:4141-9. 2001
    ..We investigated tumor- and patient-related features that might influence the response to perioperative chemotherapy (PeCT) compared with no adjuvant therapy for patients with node-negative breast cancer...
  14. ncbi request reprint Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group
    M Colleoni
    European Institute of Oncology, Milan, Italy
    J Clin Oncol 18:584-90. 2000
    ....
  15. ncbi request reprint Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
    S Aebi
    University Hospital Inselspital, Bern, Switzerland
    Lancet 355:1869-74. 2000
    ..Therefore, the outcome of adjuvant therapy was analysed in a population of young (<35 years) premenopausal patients treated in four randomised controlled trials...
  16. ncbi request reprint Prediction of response to primary chemotherapy for operable breast cancer
    M Colleoni
    Department of Medicine and Radiotherapy, Istituto Europeo di Oncologia, Milan, Italy
    Eur J Cancer 35:574-9. 1999
    ..05). These markers might be useful for tailoring primary and postsurgical systemic treatments...
  17. pmc Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity
    R Torrisi
    Department of Medicine, Research Unit of Medical Senology, European Institute of Oncology Milan, Milan, Italy
    Br J Cancer 99:1564-71. 2008
    ..In conclusion, bevacizumab is feasible and active in association with primary chemoendocrine therapy for ER-positive tumours in terms of proliferation inhibition, clinical response and antiangiogenic activity...
  18. pmc Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX
    S Aebi
    Division of Medical Oncology, Berne University Hospital and Swiss Group for Clinical Cancer research, Berne, Switzerland
    Ann Oncol 22:1981-7. 2011
    ..The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-positive lymph node-negative breast cancer is being reassessed...
  19. ncbi request reprint Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen
    L Orlando
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Anticancer Res 21:4135-9. 2001
    ....
  20. ncbi request reprint Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) resistant to taxol plus gemcitabine
    T De Pas
    Divisions of Medical Oncology, European Institute of Oncology, Via Ripamonti, 435, 20141 Milan, Italy
    Lung Cancer 31:267-70. 2001
    ..We recommend the use of this regimen for patients not refractory to primary treatment...
  21. doi request reprint A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer
    M Colleoni
    Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:1178-84. 2009
    ..We aimed to predict disease-free survival (DFS) in patients who failed to achieve a pathologic complete remission (pCR) after preoperative chemotherapy (PC)...
  22. pmc Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer
    R Torrisi
    Research Unit of Medical Senology, European Institute of Oncology Milan, Via Ripamonti 435, Milan, Italy
    Br J Cancer 97:802-8. 2007
    ..A biological response in terms of downregulation of phosphorylated ERalpha was observed in all patients. Future investigations might focus on treatments of longer duration...
  23. pmc Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer
    J Bernhard
    IBCSG Coordinating Center, Bern, Switzerland
    Br J Cancer 91:1893-901. 2004
    ..Q-TWiST analysis based on patient ratings is feasible in large-scale cross-cultural clinical trials...
  24. ncbi request reprint Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase
    M Colleoni
    Department of Medicine, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1477-83. 2003
    ....
  25. ncbi request reprint Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects
    M Colleoni
    Division of Medical Oncology, University of Milan School of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:232-8. 2006
    ..We previously demonstrated efficacy and impact on serum vascular endothelial growth factor (VEGF) for metronomic cyclophosphamide (C) and methotrexate (M) in patients with breast cancer. New metronomic schedules were investigated...
  26. pmc Adverse prognostic value of peritumoral vascular invasion: is it abrogated by adequate endocrine adjuvant therapy? Results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy for early breast cancer
    G Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    Ann Oncol 21:245-54. 2010
    ..Peritumoral vascular invasion (PVI) may assist in assigning optimal adjuvant systemic therapy for women with early breast cancer...
  27. ncbi request reprint Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy
    M Colleoni
    Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 19:465-72. 2008
    ..To identify the role of estrogen (ER), progesterone (PgR), epidermal growth factor 1 (HER1), and HER2 receptors in predicting response to preoperative chemotherapy...
  28. doi request reprint Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure
    E Montagna
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy
    Breast Cancer Res Treat 118:385-94. 2009
    ..Treatment recommendations for systemic therapy should not take into account the presence of a single micrometastatic lymph node identified during complete serial sectioning of sentinel node(s)...
  29. ncbi request reprint Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study
    F Nole
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 12:95-100. 2001
    ....
  30. doi request reprint Outcome of special types of luminal breast cancer
    M Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:1428-36. 2012
    ..The identification of special types of breast cancer might be of value in assessing prognosis and predicting response to therapy...
  31. ncbi request reprint Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease
    M Colleoni
    Research Unit in Medical Senology, Department of Medicine, Instituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 17:1497-503. 2006
    ..There is limited knowledge about prognosis, and treatment effects in young women with node-negative disease...
  32. ncbi request reprint Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors
    M Colleoni
    Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 11:1057-9. 2000
    ..To test this hypothesis we evaluated the responsiveness to preoperative chemotherapy in patients with ER and progesterone receptors (PgR)-absent tumors...
  33. doi request reprint Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report
    E Munzone
    Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, Milan, Italy
    Breast 19:33-7. 2010
    ..Pegylated liposomal-doxorubicin (PLD) pharmacokinetic characteristics support the rationale for using the drug in a metronomic fashion, potentially able to combine anthracyclines efficacy to a low toxicity profile...
  34. ncbi request reprint Brain metastases in patients with advanced breast cancer
    G Sanna
    Department of Oncology, European Institute of Oncology, Milan, Italy
    Anticancer Res 27:2865-9. 2007
    ..The incidence of brain metastases (BM) is apparently rising in patients with advanced breast cancer (ABC). We performed a case control study to define current features of breast cancer related to central nervous system (CNS) metastases...
  35. doi request reprint Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer
    G Cancello
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 21:1974-81. 2010
    ..There is limited knowledge about prognosis of selected breast cancer subtypes among very young women...
  36. ncbi request reprint Breast cancer diagnosed during pregnancy and lactation: biological features and treatment options
    O Gentilini
    Department of Breast Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Eur J Surg Oncol 31:232-6. 2005
    ..Assessment of biological features and treatment of patients with breast cancer presenting during pregnancy or lactation...
  37. pmc The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
    M Colleoni
    Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy
    Ann Oncol 20:1344-51. 2009
    ..The role of adjuvant dose-intensive chemotherapy and its efficacy according to baseline features has not yet been established...
  38. ncbi request reprint Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer
    O Pagani
    Istituto Oncologico della Svizzera Italiana, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 10:539-45. 1999
    ....
  39. ncbi request reprint Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG)
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:489-93. 1998
    ..Therefore, adherence to the 'classical' dose and schedule is recommended when CMF is used in adjuvant therapy...
  40. ncbi request reprint High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy
    S Zurrida
    Division of Senology, European Institute of Oncology, Milan, Italy University of Milan, School of Medicine, Milan, Italy Electronic address
    Eur J Cancer 49:3083-92. 2013
    ..In the present study on a subgroup GRISO cases our aim was to assess the prognostic importance of tumour biological factors after more than 10 years of follow-up...
  41. doi request reprint Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction
    M C Kneubil
    Division of Plastic Reconstruction Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milano, Italy
    Eur J Surg Oncol 39:260-5. 2013
    ..The LRR also varies according to breast cancer subtypes and clinicopathological features...
  42. pmc Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial
    G Viale
    International Breast Cancer Study Group Central Pathology Office, Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    Ann Oncol 22:2201-7. 2011
    ..Because there may be contraindications to their use based on side-effects or cost, we investigated subgroups in which aromatase inhibitors may be more or less important...
  43. doi request reprint Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study
    A Guerrieri-Gonzaga
    Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy
    Ann Oncol 21:949-54. 2010
    ..Since low-dose tamoxifen showed a favorable modulation of breast cancer biomarkers in phase II trials, a monoinstitutional cohort of women with DIN treated with low-dose tamoxifen or no systemic treatment was analyzed...
  44. ncbi request reprint Detection by denaturant gradient gel electrophoresis of tumor-specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer
    G Ferretti
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Clin Cancer Res 6:2393-400. 2000
    ..8% test accuracy. The method proposed demonstrated to be specific, accurate, and at relatively low cost but limited by low sensitivity in detecting the presence of neoplastic cells in patients with resectable non-small cell lung cancer...
  45. ncbi request reprint A phase II study of primary dose-dense sequential doxorubicin plus cyclophosphamide and docetaxel in cT4 breast cancer
    R Torrisi
    Medical Senology Research Unit, Department of Medicine, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy
    Anticancer Res 26:3861-4. 2006
    ..Dose-dense chemotherapy with anthracyclines and taxanes has improved either disease free survival or overall survival in high risk patients with early breast cancer...
  46. ncbi request reprint Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer
    M Colleoni
    Research Unit in Medical Senology at the Department of Medicine, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 18:1632-40. 2007
    ..4%), focal (368, 14.1%), moderate (51, 2.0%) and extensive (170, 6.5%)...
  47. ncbi request reprint Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies
    M Colleoni
    Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 15:1633-9. 2004
    ..While data exist to clearly correlate small tumor size to better prognosis, the fact that very small breast cancers may express biological markers of dire prognosis leads many to ignore small tumor size during treatment decision-making...
  48. ncbi request reprint Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group
    A Goldhirsch
    Department of Medicine and Radiation Oncology, European Institute of Oncology, Milan, Italy
    J Clin Oncol 16:1358-62. 1998
    ..These drugs have since been extensively used with or without endocrine therapies and/or other cytotoxic agents. Although doses and schedules have varied widely, the combination of these three drugs is generically referred to as CMF...
  49. ncbi request reprint Identifying breast cancer patients at high risk for bone metastases
    M Colleoni
    International Breast Cancer Study Group, Division of Medical Oncology, European Institute of Oncology, Milan, Ospedali Civili, Brescia, Italy The International Ludwig Breast Cancer Study Group
    J Clin Oncol 18:3925-35. 2000
    ..To identify patient populations at high risk for bone metastases at any time after diagnosis of operable breast cancer, because these patients are potential beneficiaries of treatment with bisphosphonates...
  50. ncbi request reprint Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation
    M Waeber
    Institute of Medical Oncology, Inselspital, University of Bern, Bern, Switzerland
    Ann Oncol 14:1215-21. 2003
    ..Seventy-nine percent of the patients were postmenopausal at randomization...
  51. ncbi request reprint Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications
    F Nole
    Division of Medical Oncology, Medical Care Unit, European Institute of Oncology, Milano, Italy
    Ann Oncol 19:891-7. 2008
    ..This study aimed to evaluate the prognostic significance of circulating tumor cells (CTCs) detection in advanced breast cancer patients...
  52. pmc Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
    M Rabaglio
    IBCSG Coordinating Center and Inselspital, Bern, Switzerland
    Ann Oncol 20:1489-98. 2009
    ..To compare the incidence and timing of bone fractures in postmenopausal women treated with 5 years of adjuvant tamoxifen or letrozole for endocrine-responsive early breast cancer in the Breast International Group (BIG) 1-98 trial...
  53. pmc Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:5569-75. 2008
    ..To evaluate the prognostic and predictive value of Ki-67 labeling index (LI) in a trial comparing letrozole (Let) with tamoxifen (Tam) as adjuvant therapy in postmenopausal women with early breast cancer...
  54. ncbi request reprint Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination
    C Catania
    Division of Medical Oncology, Unit for Medical Care, Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:1969-75. 2007
    ..In order to further improve quality of life of patients undergoing treatment for ABC, a new regimen using oral vinorelbine (oVNR) (d1 + d3) plus q3wks T was tested (ToVNR)...
  55. ncbi request reprint High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible?
    T De Pas
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:917-9. 1998
    ..Adriamycin (ADM) and ifosfamide (IFO) are the two most active agents in the treatment of soft tissue sarcomas (STS) with a clear dose-response relationship. We evaluated the feasibility and toxicity of a high-dose IFO-plus-ADM combination...
  56. pmc Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
    Olivia Pagani
    Oncology Institute of Southern Switzerland, Ospedale Italiano, Viganello, Lugano, Switzerland
    Breast Cancer Res Treat 116:491-500. 2009
    ..03). Chemotherapy significantly improves disease-free survival for postmenopausal women with endocrine-responsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high...
  57. ncbi request reprint Dose-finding study of weekly docetaxel, anthracyclines plus fluoropyrimidines as first-line treatment in advanced breast cancer
    O Pagani
    Institute of Oncology of Southern Switzerland IOSI, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 16:1609-17. 2005
    ....
  58. ncbi request reprint Endocrine therapy of breast cancer
    A Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:61-8. 2002
  59. doi request reprint Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse
    G Cancello
    Research Unit in Medical Senology, Department of Medicine, European Institute of Oncology, Milan 20141, Italy
    Ann Oncol 24:661-8. 2013
    ..The immunohistochemical (IHC) evaluation of estrogen receptor (ER), progesterone receptor (PgR), Ki-67 and HER2 is considered a surrogate means for identifying the molecular subtypes of breast cancer with different prognosis...
  60. doi request reprint Breast cancer subtypes and outcome after local and regional relapse
    E Montagna
    Department of Medicine, Division of Medical Oncology, Research Unit of Medical Senology, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:324-31. 2012
    ..To evaluate the outcome of breast cancer patients after locoregional recurrence (LRR) according to tumor biological features evaluated at first diagnosis and at the time of recurrence...
  61. ncbi request reprint Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors
    G Sanna
    European Institute of Oncology, Medical Oncology, University of Milan Bicocca, Milan, Italy
    Ann Oncol 18:288-92. 2007
    ..The primary end points were disease-free survival (DFS) and overall survival (OS)...
  62. ncbi request reprint Preoperative systemic treatment: prediction of responsiveness
    M Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Breast 12:538-42. 2003
    ..g. endocrine primary therapy) might be more useful...
  63. ncbi request reprint Cisplatin, etoposide and continuous infusion bleomycin in patients with testicular germ cell tumors: efficacy and toxicity data from a retrospective study
    G Curigliano
    Division of Medical Oncology, Universita di Milano, Milan, Italy
    J Chemother 21:687-92. 2009
    ..The main limitations of our study are related to the retrospective analysis, the limited number of patients and the restricted follow-up time. A prolonged follow-up is necessary to evaluate long term toxicity and outcome...
  64. ncbi request reprint Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
    F Bertolini
    Haematology Oncology, IRCCS European Institute of Oncology, Milan, Italy
    Br J Haematol 106:504-9. 1999
    ..Our data suggest that b-FGF and, particularly, VEGF might be considered prognostic factors in NHL staging and management...
  65. ncbi request reprint A randomized, prospective trial of central venous ports connected to standard open-ended or Groshong catheters in adult oncology patients
    R Biffi
    Division of General Surgery, European Institute of Oncology, Milan, Italy
    Cancer 92:1204-12. 2001
    ..The authors investigated the two types of catheters in a randomized trial using the same type of subcutaneous port and evaluated efficacy as well as early and late complications...
  66. ncbi request reprint Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer
    T De Pas
    Division of Medical Oncology, European Institute of Oncology, Milano, Italy
    Ann Oncol 11:821-7. 2000
    ..We performed a phase I study to determine the maximum-tolerated dose (MTD), antitumor activity and pharmacokinetics of GEM and TAX given weekly in chemo-naïve patients with advanced NSCLC...
  67. ncbi request reprint Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer
    F Nole
    European Institute of Oncology, Milan, Italy
    Ann Oncol 17:322-9. 2006
    ....
  68. doi request reprint Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
    G Cancello
    Unit of Research in Medical Senology, Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast Cancer Res Treat 127:713-20. 2011
    ..In conclusion, women with small size, node-negative, breast cancer are at higher risk of relapse if with HER2-positive endocrine receptor absent or Triple Negative disease...
  69. ncbi request reprint Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype
    L Orlando
    Division of Medical Oncology, Department of Medicine, Division of Pathology and Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Ann Oncol 16:1094-9. 2005
    ..We retrospectively evaluated the clinical relevance of selected immunohistochemical features of tumors in three cohorts of patients with typical medullary (MC), 'atypical' medullary (AMC) or ductal (DC) breast carcinoma...
  70. doi request reprint Should liver metastases of breast cancer be biopsied to improve treatment choice?
    G Curigliano
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milan, Italy
    Ann Oncol 22:2227-33. 2011
    ....
  71. doi request reprint Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases
    E Munzone
    Department of Medicine, Division of Medical Oncology, Istituto Europeo di Oncologia, Milano, Italy
    Ann Oncol 23:2884-90. 2012
    ..Patients with metastatic breast cancer to the ovary, without tumor debulking and after systemic therapy, have a 5-year survival rate < 10%...
  72. doi request reprint Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution
    E Botteri
    Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy
    Breast Cancer Res Treat 134:1221-8. 2012
    ..PVI and Ki-67 might help tailoring PMRT indications among patients with positive LNs. Finally, the very low incidence of recurrences in the axillary LNs raises questions about the inclusion of the axilla in the radiation field...
  73. doi request reprint CMF revisited in the 21st century
    E Munzone
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 23:305-11. 2012
    ..In conclusion, although we have learned a lot from the use of CMF, many questions are still open and hopefully stimulate our thinking, as clinicians, leading us to find new and more effective ways to treat breast cancer...
  74. ncbi request reprint Systemic treatments for women with breast cancer: outcome with relation to screening for the disease
    A Goldhirsch
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 14:1212-4. 2003
    ..Research with tailored approaches on alternative imaging for early detection of breast cancer in high-risk women and on treatments offered according to proper criteria of responsiveness to therapies is warranted...
  75. pmc Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF
    M Colleoni
    European Institute of Oncology, Milan, Italy
    Br J Cancer 86:1705-14. 2002
    ....
  76. ncbi request reprint When can a second conservative approach be considered for ipsilateral breast tumour recurrence?
    O Gentilini
    Division of Breast Surgery, European Institute of Oncology, Milan, Italy
    Ann Oncol 18:468-72. 2007
    ..Mastectomy is considered the treatment of choice in patients with ipsilateral breast tumour recurrence (IBTR) after breast-conserving surgery (BCS)...
  77. doi request reprint Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer
    Franco Nole
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Cancer Chemother Pharmacol 64:673-80. 2009
    ..In an effort to improve patient convenience and to prolong infusion-free survival, we investigated in first-line treatment a regimen combining oral vinorelbine and capecitabine in a phase II study...
  78. ncbi request reprint Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
    P Mancuso
    Division of Hematology-Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Blood 97:3658-61. 2001
    ..Blood. 2001;97:3658-3661)..
  79. ncbi request reprint Vinorelbine-based chemotherapy in hormone-refractory prostate cancer
    M G Zampino
    Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Anticancer Res 26:2375-80. 2006
    ..In this phase II study, the combination of Vinorelbine with 5-Fluorouracil and folinic acid (FLN regimen) was evaluated in patients with progressive or resistant disease after hormone therapy...
  80. pmc Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
    J Bernhard
    IBCSG Coordinating Center, Effingerstrasse 40, Bern 3008, Switzerland
    Br J Cancer 98:25-33. 2008
    ..Thus, QL considerations should not be prohibitive if future intensive therapies show superior efficacy...
  81. ncbi request reprint Very young women (<35 years) with operable breast cancer: features of disease at presentation
    M Colleoni
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:273-9. 2002
    ..Breast cancer rarely occurs in young women. Our knowledge about disease presentation, prognosis and treatment effects are largely dependent upon older series...
  82. ncbi request reprint New treatments for breast cancer: breakthroughs for patient care or just steps in the right direction?
    A Goldhirsch
    Department of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 9:973-6. 1998
    ..All three subjects represent important advances in cancer medicine...
  83. ncbi request reprint Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay
    G Curigliano
    Department of Medicine, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:895-902. 2002
    ..No studies exist on the role of these factors in male breast carcinoma...
  84. ncbi request reprint Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study
    O Pagani
    Istituto Oncologico della Svizzera Italiana, Ospedale S Giovanni, Bellinzona, Switzerland
    Ann Oncol 11:985-91. 2000
    ..We report here the overall results of the combination of epidoxorubicin (E) 90 mg/m2 and docetaxel (D) 75 mg/m2 as first-line chemotherapy in ABC...
  85. ncbi request reprint Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels
    M Colleoni
    Division of Medical Oncology, European Institute of Oncology, Milan, Italy
    Ann Oncol 13:73-80. 2002
    ..Alternative mechanisms of efficacy have been ascribed to several common anticancer agents, including cyclophosphamide (CTX), methotrexate (MTX), anthracyclines and taxanes, postulating an antiangiogenic activity...
  86. ncbi request reprint Breast cancer vaccines: a clinical reality or fairy tale?
    G Curigliano
    Department of Medicine, Clinical Pharmacology and New Drugs Development Unit, Division of Experimental Oncology, Laboratory of Experimental Immunology, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:750-62. 2006
    ..The review discusses possible future directions for vaccine development and applications in the adjuvant setting...
  87. ncbi request reprint Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis
    G Curigliano
    European Institute of Oncology, Division of Medical Oncology, Milano, Italy
    Anticancer Res 21:3015-20. 2001
    ..The diagnosis and follow-up of patients with T1 bladder cancer relies invasive procedures. We developed a non-invasive method for detection of T1 bladder cancer based on a feasible non-radioactive molecular approach...
  88. ncbi request reprint Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab
    E Munzone
    Department of Medicine, Division of Medical Oncology, Day Hospital Unit, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Breast 14:380-3. 2005
    ..The susceptibility of ocular metastases to this approach seems different to that of other sanctuary disease sites...
  89. ncbi request reprint Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer
    G Sanna
    Department of Medicine, Unit for Medical Care, European Institute of Oncology, Milan, Italy
    Ann Oncol 17:1512-6. 2006
    ..In recent years, several cases of mandibular necrosis associated with long-term use of bisphosphonates have been reported. The estimated incidence varies from 1% to 4.6%...
  90. doi request reprint The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy
    A Chiappa
    Department of General Surgery Laparoscopic Surgery, University of Milano, European Institute of Oncology, Milano, Italy
    Crit Rev Oncol Hematol 72:65-75. 2009
    ....
  91. ncbi request reprint Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy
    F Roila
    Divisione Oncologia Medica, Ospedale Policlinico, Perugia, Italy
    Ann Oncol 14:843-8. 2003
    ..We audited prescriptions of adjuvant systemic therapies for Italian breast cancer patients and compared them with recommendations of an International Consensus Panel...
  92. ncbi request reprint Lesson learned from high-dose chemotherapy for high-risk breast cancer (What you see is what you mean)
    M Colleoni
    Ann Oncol 15:355-6. 2004
  93. ncbi request reprint Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer
    H J Senn
    Center for Tumordetection Prevention ZeTuP, Rorschacherstrasse 150, CH 9006 St Gallen, Switzerland
    Breast 12:569-82. 2003
    ....
  94. ncbi request reprint Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG)
    L Biganzoli
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 15:207-10. 2004
    ..To collect oncologists' experience and opinion on adjuvant chemotherapy in elderly breast cancer patients...
  95. ncbi request reprint Can tamoxifen relieve motion sickness?
    L Gianni
    Ann Oncol 16:1713-4. 2005
  96. ncbi request reprint Treatment of advanced breast cancer: the good, the bad and the ugly
    M Colleoni
    Ann Oncol 16:1219-21. 2005
  97. ncbi request reprint Tailoring adjuvant treatments for the individual breast cancer patient
    R D Gelber
    IBCSG Statistical Center, Department of Biostatistical Science, Dana Farber Cancer Institute, 44 Binney Str, Boston, MA 02115, USA
    Breast 12:558-68. 2003
    ..Unfortunately, information currently available is insufficient to properly tailor adjuvant treatments...
  98. ncbi request reprint Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00)
    L Perey
    Swiss Group for Clinical Cancer Research SAKK, Bern, Switzerland
    Ann Oncol 18:64-9. 2007
    ..The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI) treatment...
  99. doi request reprint Anthracyclines for gestational breast cancer: course and outcome of pregnancy
    H A Azim
    Ann Oncol 19:1511-2. 2008
  100. doi request reprint Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
    ..PERCHE closed with inadequate accrual; TEXT accrued rapidly...
  101. doi request reprint Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
    M Untch
    Helios Klinikum Berlin Buch, Academic Hospital of the University Charite Berlin, Berlin, Germany
    Ann Oncol 19:1090-6. 2008
    ..We aimed to assess the magnitude of its clinical benefit for subpopulations defined by nodal and steroid hormone receptor status using data from the Herceptin Adjuvant (HERA) study...